protein Inhibitors
2 drugsAbout protein
The protein target's precise function requires further investigation, but it interacts with two FDA-approved drugs. Modulating its activity has a tangible effect on disease processes, though specific mechanisms are still being elucidated.
There is currently no genetic evidence linking this protein to specific diseases. Despite the lack of genetic validation, the clinical success of PENTAM and PENTAMIDINE ISETHIONATE warrants further research.
Two drugs, PENTAM and PENTAMIDINE ISETHIONATE, are approved to target this protein, both are small molecules. These drugs are used in the 'Other' therapeutic area, outside major disease categories.
Top protein Drugs
Fresenius Kabi and SETON PHARMS are the companies with approved drugs.
Low competition suggests an opportunity for new market entrants.
protein Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets protein, using small molecule modality.
Explore alternative modalities to differentiate from existing drugs.
protein Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on protein. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 | 75% |
| Phase 2 | 2 | 1 | 1 | 0 | 50% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
protein Drug Approval Timeline (1984 - 1984)
The first drug was approved in 1984 and the most recent in 1992.
The long gap since the last approval indicates potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on protein. A trial counts if an approved drug acting on protein is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.